Epizyme

EPZM NASDAQ
12.86
+0.28
+2.23%
After Hours: 12.86 0 0.00% 16:51 05/22 EDT
Open
12.56
Prev Close
12.58
High
13.03
Low
12.52
Volume
632.37K
Avg Vol (3M)
782.80K
52 Week High
18.70
52 Week Low
5.14
% Turnover
0.69%
Market Cap
1.17B
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Company Profile

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule inhibitors of other chromatin modifying proteins (CMPs). The Company's lead product candidate, tazemetostat, is a potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2) histone methyltransferases (HMT), an enzyme that plays an important role in various cancers. The Company is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), and one Phase I study in children with molecularly defined solid tumors. The Company owns the global development and commercialization rights to tazemetostat outside of Japan.
MORE >

Recently

Name
Price
%Change